Ravuconazole (CAS 170864-29-6) Suppliers and Product Information

Ravuconazole is a second-generation triazole antifungal agent. It inhibits cytochrome P450 14α-demethylase, an enzyme in the sterol biosynthesis pathway. It shows potent activity against Candida spp. and has a broader spectrum of activity compared to fluconazole and itraconazole. It is also effective against Cryptococcus neoformans, Aspergillus fumigatus, dermatophytes, and dematiaceous fungi.

Frequently Asked Questions

Q: What is the mechanism of action of Ravuconazole?

A: Ravuconazole inhibits the P450-dependent enzyme lanosterol 14-α-demethylase, resulting in depletion of ergosterol and accumulation of 14-α-demethylated precursors. This interferes with the function of ergosterol in fungal membranes and compromises membrane integrity.

Q: What are the potential side effects of Ravuconazole?

A: In human volunteers, doses up to 2.5 mg/kg/day have shown minimal hepatotoxicity and nephrotoxicity. The most frequently reported side effects include headache, abdominal pain, diarrhea, pruritus, and rash.

Q: Are there any significant drug interactions with Ravuconazole?

A: Ravuconazole may have a lower potential for drug interactions compared to other azoles, as it is a less potent inhibitor of CYP3A4 than voriconazole. However, one clinical trial found that rifampicin reduced ravuconazole levels by over 50%.